For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service at certain sites in the UK for patients who meet the eligibility criteria.
Here you can find out more about BRCA testing, what the AstraZeneca
Tumour BRCA testing service
Who is eligible for this service?
Patients who are eligible for this service are those that have ovarian cancer and either a known negative germline BRCA mutation status or an unknown germline BRCA mutation status. Patients must have received at least two prior lines of treatment (i.e.
How to access the service
You can access the service by completing the relevant AstraZeneca tumour BRCA testing form (below) and sending this, along with the tumour sample, to one of the AstraZeneca collaboration laboratories. The results should be returned 4-6 weeks after receipt of patient form and sample. The three collaboration laboratories AstraZeneca are currently working with to offer this service are:
All Wales Genetic Laboratory, Cardiff
All Wales Genetics Laboratory
Institute of Medical Genetics
University Hospital of Wales
Cardiff CF14 4XW
Tel: 02920 742641
Genomic Diagnostic Laboratory, Manchester
Genomic Diagnostics Laboratory Genetic Medicine (6th Floor)
St. Mary’s Hospital Oxford Road
Manchester M13 9WL
Tel: 0161 276 3265/6122
Clinical Genomics, The Royal Marsden
Centre for Molecular Pathology
The Royal Marsden NHSFT
15 Cotswold Road, Sutton
Surrey SM2 5NG
Tel: 020 8915 6565
The testing process is straightforward and can be completed in several simple steps.